Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DCLK1 | O15075 | 5/20 | 0.49 |
| ▸ | LRRK2 | Q5S007 | 5/20 | 0.49 |
| ▸ | MAPK7 | Q13164 | 5/20 | 0.49 |
| ▸ | ULK1 | O75385 | 1/20 | 0.45 |
| ▸ | TNK2 | Q07912 | 4/20 | 0.43 |
| ▸ | FGFR1 | P11362 | 3/20 | 0.43 |
| ▸ | KDR | P35968 | 3/20 | 0.43 |
| ▸ | EPHB4 | P54760 | 3/20 | 0.43 |
| ▸ | JAK1 | P23458 | 2/20 | 0.42 |
| ▸ | JAK3 | P52333 | 2/20 | 0.42 |
| ▸ | GAK | O14976 | 1/20 | 0.41 |
| ▸ | BRD4 | O60885 | 1/20 | 0.41 |
| ▸ | TNK1 | Q13470 | 1/20 | 0.41 |
| ▸ | DCLK2 | Q8N568 | 1/20 | 0.41 |
| ▸ | STAT6 | P42226 | 1/20 | 0.40 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.40 |
| ▸ | JAK2 | O60674 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22680705 | 0.93 | DCLK1 (0.52) | DCLK1LRRK2MAPK7TNK2FGFR1 | |
| SCHEMBL22680895 | 0.86 | LRRK2 (0.51) | DCLK1LRRK2MAPK7TNK2FGFR1 | |
| SCHEMBL22680883 | 0.86 | TNK2 (0.56) | DCLK1LRRK2MAPK7TNK2GAK | |
| SCHEMBL22680790 | 0.86 | LRRK2 (0.69) | DCLK1LRRK2MAPK7TNK2GAK | |
| SCHEMBL22680785 | 0.82 | DCLK1 (0.50) | DCLK1LRRK2MAPK7TNK2GAK | |
| SCHEMBL22680789 | 0.78 | LRRK2 (0.69) | DCLK1LRRK2MAPK7TNK2GAK | |
| SCHEMBL22680698 | 0.77 | STK4 (0.63) | DCLK1LRRK2MAPK7STK4 | |
| SCHEMBL17469525 | 0.77 | MARK3 (0.49) | DCLK1LRRK2MAPK7JAK3BRD4 | |
| SCHEMBL17469560 | 0.75 | DCLK1 (0.51) | DCLK1LRRK2MAPK7TNK2JAK1 | |
| SCHEMBL22680887 | 0.72 | DRD2 (0.44) | MAPK7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11279707-B2 | NEK inhibitors and methods of use | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-03-22 | — | — | US | disclosed |
| US-20200361948-A1 | NEK INHIBITORS AND METHODS OF USE | DANA-FARBER CANCER INSTITUTE, INC. | 2020-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200361948-A1 | NEK INHIBITORS AND METHODS OF USE | NEK5, NEK2, NEK1 | DCLK1 188/4885LRRK2 3010/4885MAPK7 911/4885 |
| US-11279707-B2 | NEK inhibitors and methods of use | NEK5, NEK2, NEK1 | DCLK1 188/4885LRRK2 3010/4885MAPK7 911/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.